AUTH/2541/11/12: GP v Napp — Flutiform email sent to NHS address (no breach)

📅 2012 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2541/11/12
ComplainantGeneral practitioner (GP)
CompanyNapp Pharmaceuticals Limited
ProductFlutiform (fluticasone/formoterol)
ChannelEmail promotion to NHS email address (sent via third-party agency)
IssueAlleged inappropriate promotional email/spam to NHS email; questioned compliance with email permission requirements
Applicable Code year2012
Clauses consideredClauses 9.1 and 9.9
Panel decisionNo breach
Key rationaleEvidence the complainant had agreed to receive promotional emails; unsubscribe information provided; company responsible for third-party activity but consent was demonstrated
Complaint received23 November 2012
Case completed20 March 2013
AppealNo appeal
Material referenceUK/FLUT-12106 (certified October 2012)

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A general practitioner (GP) received a promotional email advertisement for Flutiform (fluticasone/formoterol) to their NHS email address.
  • The GP complained that a publicly funded NHS email network should not be used for this type of advertising and raised concerns about undue influence and “spam”.
  • Napp stated the email was sent by a third-party agency it had contracted, and that the recipient had previously opted in/consented to receive promotional emails via that agency’s service.
  • The agency’s registration and re-registration process told healthcare professionals they would receive emails that could include pharmaceutical promotional material, and provided an unsubscribe option.
  • The Panel considered the email to be promotional and noted companies remain responsible for third parties acting on their behalf.
⚖️

Outcome

  • No breach of Clause 9.9 (email promotion requires prior permission) because there was evidence the complainant had agreed to receive promotional emails.
  • No breach of Clause 9.1 (high standards) as a consequence of the finding under Clause 9.9.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training